Language
English
6
Average: 6 (1 vote)
Abstract
Ibogaine is a psychoactive alkaloid derived from the west-African shrub Tabernanthe iboga. Western cultures are increasing the interest for the substance due to its claimed anti addictive properties, although the evidence supporting this effect is still preliminary. The use of ibogaine often occurs with no medical supervision in uncontrolled settings, and its use has been associated with several reports of severe adverse events. This review aims to evaluate the clinical studies of ibogaine, with a focus on administration settings, to elucidate specific criteria that may promote safer contexts for ibogaine use. A systematic review of the literature was conducted based on PRISMA guidelines. PubMed, Scielo, ClinicalTrials.gov and Core.ac.uk electronic databases were searched, and clinical studies published until November 17, 2022, were retrieved. The final synthesis included 12 sources. Information about general characteristics of the studies, adverse effects, screening of participants and setting characteristics were summarized and discussed. It is concluded that the use of controlled settings, supported by trained professionals and equipment allowing for rigorous medical, psychiatric, and cardiac monitoring, are essential to promote the safety of patients receiving ibogaine.
Juliana Mendes Rocha 1, José A S Reis 1, José Carlos Bouso 1 2 3, Jaime E C Hallak 1 2 4, Rafael G Dos Santos 5 6 7
Affiliations expand
- PMID: 36947216
- DOI: 10.1007/s00406-023-01590-1
Keywords: Ibogaine; Noribogaine; Safety; Setting.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Similar articles
-
The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).
Ona G, Rocha JM, Bouso JC, Hallak JEC, Borràs T, Colomina MT, Dos Santos RG.Psychopharmacology (Berl). 2022 Jun;239(6):1977-1987. doi: 10.1007/s00213-021-05964-y. Epub 2021 Aug 18.PMID: 34406452 Review. -
How toxic is ibogaine?
Litjens RP, Brunt TM.Clin Toxicol (Phila). 2016;54(4):297-302. doi: 10.3109/15563650.2016.1138226. Epub 2016 Jan 25.PMID: 26807959 Review. -
Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.
Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V.Hum Exp Toxicol. 2008 Mar;27(3):181-94. doi: 10.1177/0960327107087802.PMID: 18650249 Review. -
A systematic literature review of clinical trials and therapeutic applications of ibogaine.
Köck P, Froelich K, Walter M, Lang U, Dürsteler KM.J Subst Abuse Treat. 2022 Jul;138:108717. doi: 10.1016/j.jsat.2021.108717. Epub 2021 Dec 30.PMID: 35012793 -
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.PMID: 36321557 Free PMC article.